Is natalizumab overshooting its rebound?

Neurology. 2008 Mar 25;70(13 Pt 2):1073-4. doi: 10.1212/01.wnl.0000306415.37679.5a.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Humanized
  • Autoimmunity / drug effects
  • Autoimmunity / immunology
  • Central Nervous System / drug effects
  • Central Nervous System / immunology
  • Central Nervous System / pathology
  • Chemotaxis, Leukocyte / drug effects
  • Chemotaxis, Leukocyte / immunology
  • Clinical Trials as Topic / statistics & numerical data
  • Drug Administration Schedule
  • Humans
  • Immunologic Factors / administration & dosage
  • Immunologic Factors / adverse effects
  • Integrin alpha4beta1 / drug effects
  • Integrin alpha4beta1 / immunology
  • Leukocytes / drug effects
  • Leukocytes / immunology
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / immunology*
  • Multiple Sclerosis / pathology
  • Natalizumab
  • Recurrence
  • Substance Withdrawal Syndrome / immunology*
  • Substance Withdrawal Syndrome / pathology
  • Substance Withdrawal Syndrome / physiopathology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Integrin alpha4beta1
  • Natalizumab